A new Medicare pilot program called Medicare GLP-1 Bridge began July 1, reducing monthly out-of-pocket costs for certain GLP-1 medications from roughly $350 to a $50 copay for eligible beneficiaries with obesity and prediabetes. The demonstration project covers Wegovy, Zepbound, and Foundayo and…
A significant shift in Medicare's approach to weight-loss medications took effect on July 1 with the launch of a federal pilot program called Medicare GLP-1 Bridge. This demonstration project is designed to dramatically lower the cost of certain GLP-1 drugs for millions of eligible beneficiaries who have obesity and prediabetes. Previously, many of these individuals were paying around $350 per month out of pocket for their prescriptions. Under the new initiative, that cost falls to a $50 copay each month.
Federal officials are using the pilot program as a test to evaluate whether expanding access to these medications can lead to better health outcomes and possibly reduce overall healthcare spending in the long term. The program operates under Medicare's research and demonstration authority, which allows the government to temporarily test new coverage models without permanently changing Medicare law.
Not all Medicare beneficiaries will qualify for the reduced copays. The pilot program has specific eligibility criteria that must be met. Individuals must have a body mass index of at least 27 and also have prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease. Alternatively, a BMI of at least 30 is required along with chronic kidney disease, a history of heart failure, or uncontrolled hypertension. For those with a BMI of at least 35, no additional health conditions are needed to qualify.
The expanded coverage includes several specific GLP-1 medications that are approved to treat obesity: Wegovy, Zepbound, and Foundayo. Beneficiaries who meet the eligibility requirements and are prescribed one of these drugs could see their monthly prescription costs drop from approximately $350 to the $50 copay level.
It is important to note that the Medicare GLP-1 Bridge program is only available to certain Medicare beneficiaries. Those who are using GLP-1 medications solely for weight loss outside of this pilot program generally remain subject to existing coverage rules and will not automatically receive the lower copay.
Supporters of the initiative argue that broader access to these medications could help prevent or delay chronic conditions such as Type 2 diabetes and cardiovascular disease. If successful, the program could potentially reduce healthcare costs over time by averting expensive treatments for these conditions later in life.
The program is temporary in nature, but it is designed to transition after 18 months into a longer initiative called the BALANCE program. According to Dr. Annie Moore, a professor of clinical medicine at the University of Colorado Anschutz Medical Center, the BALANCE program will last a total of five years. Moore expressed hope that this extended time frame would provide budget neutrality, with cost savings offsetting the expense of the medications.
Dr. Annie Moore provided additional insights into the significance of the program. She stated, "Hopefully history will reflect this, Medicare's commitment to prevention, health promotion rather than all sick care." This comment highlights the broader shift in Medicare's philosophy from treating diseases after they occur to preventing them from developing in the first place.
However, Moore also raised concerns about certain groups of patients who may be excluded from the pilot program. She noted that the "sickest patients are disqualified," particularly those with moderate to severe sleep apnea or Type 2 diabetes. These individuals would face the standard Medicare medication deductible of $2,400 per year instead of the $600 per year cost offered through the Bridge program. This disparity means that some of the patients who might benefit most from GLP-1 medications could end up paying significantly more.
According to a recent Healthcare Pulse Survey conducted by eHealth, 39% of respondents said they would be interested in trying a GLP-1 drug if it were covered by Medicare. The survey also indicated that prescription drug affordability remains one of the biggest healthcare concerns for many Medicare-eligible adults. The lower out-of-pocket costs under this pilot program could make these medications more accessible for beneficiaries who previously found them financially out of reach.
Beneficiaries who are interested in the new coverage should take several steps to determine their eligibility. First, they should check with their Medicare Advantage or Part D prescription drug plan to see if they meet the pilot program's requirements. They should also consult with their healthcare provider to confirm whether their prescribed medication is included in the program.
The demonstration program is only one part of Medicare's evolving approach to weight-loss medications. Its results could help shape future Medicare policy as lawmakers and federal health officials continue to debate whether weight-loss medications should play a larger role in preventing chronic disease among older Americans.
The Medicare plans represented in this program include PDP, HMO, PPO, or PFFS plans with a Medicare contract. Enrollment in these plans depends on contract renewal. Not all plans offer all of these benefits, and benefits may vary by carrier and location. Limitations and exclusions may apply. $0 premium plans are not available in all areas, and beneficiaries must continue to pay their Medicare Part B premium. This program is not affiliated with or endorsed by any government agency. Every year, Medicare evaluates plans based on a 5-star rating system.
This information is provided for educational purposes and does not constitute a solicitation of insurance. Enrollment in a plan may be limited to certain times of the year unless the beneficiary qualifies for a special election or enrollment period or is in their Medicare Initial Election Period.
The launch of the Medicare GLP-1 Bridge program marks a notable shift in the federal government's approach to weight-loss medications. By temporarily lowering costs and expanding coverage, officials hope to gather data that will inform future decisions about whether to make these drugs more broadly available to the Medicare population. The program's outcomes over the next several years will be closely watched by policymakers, healthcare providers, and patients alike.
Peptides referenced: Semaglutide, Tirzepatide, GLP-1.
Related reading: Study Flags Need to Monitor Frailty Risks With GLP-1 Drugs for Older Adults, Eli Lilly Makes Equity Investment in Wearable Ring Startup Oura, The Unapproved Weight-Loss Drug That Is Very Online, GLP-1 Maker Eli Lilly Funded Clinical Trials at Chinese Military Sites.